Barrick Mining Corporation Stock Price, News & Analysis

Cereno Scientific (Nasdaq First North: B) will attend JPM Week 2026 in San Francisco and participate at the Biotech Showcase from January 12–18, 2026, with Biotech Showcase sessions running January 12–14, 2026.

The company said it will hold investor and partner meetings throughout the week to discuss progress across its HDAC inhibitor portfolio, including advancement of lead candidate CS1 toward a global Phase IIb trial in PAH and Phase I data supporting CS014 moving into Phase II. Investors can request meetings via the Biotech Showcase partnering platform or by emailing business.development@cerenoscientific.com. For IR contact, use tove.bergenholt@cerenoscientific.com or phone +46 73-236 62 46.

ETQ (NYSE:B) was ranked a Front Runner in the Enterprise Quality Management Software Solution Selection Matrix 2025 by LNS Research on Dec 11, 2025. Out of 16 vendors evaluated, ETQ was one of three Front Runners.

LNS cited ETQ Reliance's extensive configurability, a unified workflow engine, strong customer support described as "agile and focused on customer success," and a broad application library. The report highlighted partnerships with Augmentir for frontline integration and Acerta for predictive quality analytics. LNS scored ETQ across Product, Potential, and Presence in its 3P model.

BioArctic (Nasdaq: B) partner Eisai announced that Leqembi (lecanemab) has been included in China’s new Commercial Insurance Innovative Drug List, effective January 1, 2026. The list enables commercial insurers to negotiate coverage products for listed innovative medicines, aiming to narrow the gap with the National Reimbursement Drug List.

Eisai launched Leqembi in China in June 2024 and estimates 17 million people had MCI or mild dementia due to Alzheimer’s in China in 2024. Leqembi was originally developed by BioArctic and is commercialized in China by Eisai; BioArctic retains Nordic commercialization rights and is preparing joint commercialization with Eisai in that region.

Cereno Scientific (B) announced that the U.S. FDA cleared initiation of its global Phase IIb trial of lead candidate CS1 for pulmonary arterial hypertension (PAH).

The randomized, double-blind, placebo-controlled, dose-finding study will enroll ~126 patients across ~65 sites in 10–12 countries, run 60 weeks total, and evaluate PVR by right-heart catheterization and 6-minute walk distance at Week 36. CS1 holds Orphan Drug and Fast Track designations. First patient in is planned for Q2 2026, with top-line data anticipated around Q4 2028 subject to enrollment timelines.

BioArctic partner Eisai (NYSE:B) presented CTAD 2025 data showing continued lecanemab (Leqembi) treatment may delay Alzheimer’s progression by up to 8.3 years in a low‑amyloid subgroup who started treatment early. Analysis used Clarity AD OLE and ADNI natural‑history data to estimate 10‑year time savings by CDR‑SB, with overall delays of 2.5–3.5 years vs untreated and larger gains in low‑amyloid patients.

Separately, a subcutaneous autoinjector (SC‑AI) approved for maintenance in the US (Aug 2025) showed bioequivalent exposure to IV dosing (exposure ratio 104%, 90% CI 99.1%–109%), low systemic infusion reactions, ADA 1.4%, and predicted ARIA‑E rates of 12.4% (30.9% in ApoE4 homozygotes). sBLA for initiation completed Nov 2025; Japan SC submission Nov 2025.

ETQ (NYSE:B) launched ETQ Reliance Go on December 3, 2025, a cloud-native electronic quality management system (EQMS) for small- to mid-sized manufacturers.

The SaaS offering provides a self-service implementation path, simple licensing-only pricing, built-in best-practice templates and on-demand training to enable administrators to deploy without IT or vendor services. Key features include AWS-based infrastructure, preconfigured processes (document control, training, audit, nonconformance), modular apps and automated performance tracking. ETQ Reliance Go is available immediately.

B (Barrick) completed the divestiture of its interests in the Tongon gold mine and certain exploration properties in Côte d’Ivoire to Atlantic Group for total consideration of up to $305 million.

The consideration comprises $192 million in cash (which includes a $23 million shareholder loan repayment payable within six months of closing) and contingent cash payments up to $113 million tied to the price of gold over 2.5 years and resource conversions over 5 years.

Barrick (NYSE:B) announced its Board has authorized management to explore an initial public offering (IPO) of a subsidiary ("NewCo") that would hold Barrick’s North American gold assets.

NewCo would be anchored by Barrick’s joint venture interests in Nevada Gold Mines and Pueblo Viejo, plus the wholly owned Fourmile discovery in Nevada. The IPO is contemplated as a listing of a small minority interest while Barrick intends to retain a significant controlling majority. The Board authorized exploration through early 2026 and the company will update progress at its Full Year 2025 Results in February 2026. Any IPO decision remains subject to Board approval, customary requirements, and market conditions.

B (Barrick) completed the divestiture of the Hemlo Gold Mine in Canada to Carcetti Capital Corp., which will be renamed Hemlo Mining Corp (HMC), for total consideration of up to $1.09 billion.

Transaction proceeds included $875 million in cash received on closing, $50 million in HMC shares received on closing, and a production and tiered gold price-linked cash payment structure of up to $165 million payable over a five-year term starting in January 2027. The company acknowledged cooperation from the Biigtigong Nishnaabeg and Netmizaaggamig Nishnaabeg First Nations.